Profile
ACHL VRTX ALNY REGN ARGX SGEN
Company Name Achilles Therapeutics plc Vertex Pharmaceuticals Incorporated Alnylam Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. argenx SE Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $60.83M $101.65B $61.42B $57.97B $46.27B $43.15B
Employees 0.20K 6.10K 2.23K 15.16K 1.60K 3.26K
CEO Iraj Ali Reshma Kewalramani FASN, Yvonne L. Greenstreet Leonard S. Schleifer Timothy Van Hauwermeiren EMBA, David R. Epstein
Ratings
ACHL VRTX ALNY REGN ARGX SGEN
Quant Rating Score 3 4 1 4 4 3
Quant Rating Neutral Buy Strong Sell Buy Buy Neutral
Trading
ACHL VRTX ALNY REGN ARGX SGEN
Last Close $1.48 $393.21 $461.14 $572.59 $756.83 $228.74
High 52 $1.49 $516.74 $482.13 $1153.08 $768 $228.74
Low 52 $0.71 $366.54 $224.58 $482.92 $519.76 $228.74
Price vs. 52 Week High -0.67 % -23.91 % -4.35 % -50.34 % -1.45 % 0 %
Price vs. 52 Week Low 108.45 % 7.28 % 105.33 % 18.57 % 45.61 % 0 %
Total Return
ACHL VRTX ALNY REGN ARGX SGEN
1 Month Return 0 % 0.11 % 2.72 % -1.35 % 15.75 % 0 %
3 Month Return 0 % -12.8 % 49.34 % 9.55 % 37.3 % 0 %
6 Month Return 3.5 % -22.1 % 90.74 % -14.14 % 25.1 % 0 %
9 Month Return 49.96 % -16 % 89 % -21.01 % 19.63 % 0 %
YTD Return 29.82 % -2.36 % 95.97 % -19.62 % 23.06 % 0 %
1 Year Return 109.63 % -19.66 % 70.56 % -50.34 % 40.69 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ACHL VRTX ALNY REGN ARGX SGEN
Dividend Yield Percentage (TTM) - - - 0.47 % - -
Dividend Paid and Capex Coverage Ration (TTM) -25.21 % 11.09 % -0.43 % 4.37 % -44.32 % -5.87 %
Dividend Per Share (TTM) - - - 2.64 % - -
Payout Ratio (TTM) - - - 4.18 % - -
Profitability
ACHL VRTX ALNY REGN ARGX SGEN
Gross Profit Margin TTM - 86.11 % 83.64 % 81.98 % 65.32 % 79.1 %
Return on Assets TTM -39.32 % 15.13 % -6.99 % 11.67 % 15.06 % -16.61 %
Return on Equity TTM -41.47 % 22.14 % -274.21 % 15.11 % 18.96 % -20.8 %
Return on Capital Employed TTM -50.39 % 19.72 % -5.52 % 11.45 % 5.04 % -21.46 %
Net Income Per EBT TTM 99.96 % 83.16 % 84.06 % 91.46 % 237.3 % 101.33 %
EBT Per Ebit TTM 91.92 % 111.48 % 210.66 % 123.23 % 147.38 % 98.26 %
EBIT Per Revenue TTM - 34.36 % -7.32 % 27.83 % 13.47 % -31.24 %
Cash Flow To Debt Ratio TTM -483.77 % 251.83 % -1.2 % 175.35 % -175.92 % -1043.73 %
Receivables Turnover TTM - 6.03 4.34 2.53 1.91 3.91
Payables Turnover TTM 0.56 0.43 3.93 3.54 0.88 1.97
Inventory Turnover TTM - 1.06 5.62 0.8 2.21 0.96
Fixed Asset Turnover TTM - 431.08 % 355.68 % 293.64 % 5009.77 % 665.41 %
Asset Turnover TTM - 47.51 % 53.92 % 37.19 % 31.97 % 53.41 %
Operating Cash Flow Per Share TTM -0.43 14.98 -0.12 45.13 -1.07 -2.46
Free Cash Flow Per Share TTM -0.45 13.63 -0.4 36.58 -1.09 -2.88
Cash Per Share TTM 212.86 % 3036 % 2203.63 % 7107.14 % 5536.58 % 939.52 %
Operating Cash Flow Sales Ratio TTM - 33.68 % -0.63 % 33.37 % -3.31 % -23.12 %
Free Cash Flow Operating Cash Flow Ratio TTM 103.97 % 90.99 % 335.21 % 81.05 % 102.26 % 117.04 %
Cash Flow Coverage Ratios TTM -483.77 % 251.83 % -1.2 % 175.35 % -175.92 % -1043.73 %
Price To Free Cash Flows Ratio TTM -3.34 29.05 -1179.18 15.08 -596.18 -81.26
Price To Operating Cash Flows Ratio TTM -3.42 26.46 -3910.39 12.33 -706.75 -93.1
Price Cash Flow Ratio TTM -3.42 26.46 -3910.39 12.33 -706.75 -93.1
Income Statement (TTM)
ACHL VRTX ALNY REGN ARGX SGEN
Revenue $0B $11.02B $2.25B $14.2B $2.19B $1.96B
Gross Profit $-0B $9.49B $1.92B $11.75B $1.96B $1.55B
Gross Profit Ratio 0% 86.11% 85.62% 82.74% 89.62% 79.1%
EBITDA $-0.07B $0.49B $-0.18B $5.32B $0.11B $-0.62B
Net Income $-0.07B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
EPS Diluted -1.74 -2.08 -2.16 38.34 12.78 -3.3
Balance Sheet (MRQ)
ACHL VRTX ALNY REGN ARGX SGEN
Long Term Debt $0B $1.66B $1.25B $2.7B $0.03B $0.04B
Total Liabilities $0.02B $6.12B $4.17B $8.41B $0.7B $0.87B
Total Equity $0.14B $16.41B $0.07B $29.35B $5.5B $2.8B
Total Investments $0B $6.65B $1.73B $15.42B $1.93B $1.42B
Total Debt $0B $1.75B $1.3B $2.7B $0.04B $0.04B
Total Assets $0.16B $22.53B $4.24B $37.76B $6.2B $3.67B
Cash Flow Statement (TTM)
ACHL VRTX ALNY REGN ARGX SGEN
Net Income $-0.07B $-0.54B $-0.28B $4.41B $0.83B $-0.61B
Inventory $0B $-0.52B $0.01B $-0.62B $-0.1B $-0.23B
Dividends Paid $0B $0B $0B $0B $0B $0B
Operating Cash Flow $-0.05B $-0.49B $-0.01B $4.42B $-0.08B $-0.45B
Capital Expenditure $-0B $-0.3B $-0.03B $-0.76B $-0.07B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 39.34
AARD Aardvark Therapeutics, Inc. Common Stock 10.24
ABCL AbCellera Biologics Inc. 4.765
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.67
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 1.22
ABPWW 0.0316
ABSI Absci Corporation 2.705
ABUS Arbutus Biopharma Corporation 4.395
ABVC ABVC BioPharma, Inc. 2.83
ABVX Abivax SA American Depositary Shares 82.28
ACAD ACADIA Pharmaceuticals Inc. 23.96
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 0.8085
ACGN Aceragen, Inc. 0.3849
ACHV Achieve Life Sciences, Inc. 3.085
ACIU AC Immune SA 2.53
ACLX Arcellx, Inc. 77.34
ETFs With Exposure to ACHL
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0.01 140.93
BIB ProShares Ultra Nasdaq Biotechnology 0 56.6
IBBQ Invesco Nasdaq Biotechnology ETF 0 23.7
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0.01 6.895
Unlock